<html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8"></head><body style="word-wrap: break-word; -webkit-nbsp-mode: space; line-break: after-white-space;" class=""><a href="https://www.politico.com/news/2021/03/21/coronavirus-vaccine-wto-477272" class="">https://www.politico.com/news/2021/03/21/coronavirus-vaccine-wto-477272</a><div class=""><div class="media-item__summary size--medium">
<h2 class="headline">Poor countries are fighting with drug companies over vaccines. Now Biden must pick a side.</h2><p class="dek">Some lawmakers want the WTO to waive patent protections
on vaccines, but drug companies say the move would cut into their
profits.</p></div></div><div class=""><p class=" story-text__paragraph">President Joe Biden is facing growing
pressure from Democrats to ensure that billions of people in poor
countries have access to Covid-19 vaccines as the United States steps up
its production and distribution of the shots.</p><p class=" story-text__paragraph">Biden has taken some first steps
toward helping other countries by pledging $4 billion to an
international effort to ensure equal access to vaccines globally and
offering to provide Mexico and Canada access to U.S. supplies of the
AstraZeneca shot.</p><div class=""><p class=" story-text__paragraph">But Democratic lawmakers and advocacy
groups are pressing him to go further by supporting a request by India,
South Africa and 55 other countries for the World Trade Organization to
waive patent protections on vaccines. Those countries argue that would
enable manufacturers around the world to copy the formulas and massively
increase production.</p><p class=" story-text__paragraph">Drug
companies, including the ones making the vaccines now authorized in the
U.S., widely oppose the move, which they say would undermine the global
response to the pandemic and not have the intended effect of speeding up
production. The Trump administration opposed it at the WTO. But House
Democrats say they have already collected close to a hundred signatures
on a letter urging Biden to change the U.S. position. Sens. <a href="https://cd.politicopro.com/member/51605" target="_blank" data-person-id="51605" class="">Bernie Sanders</a> (I-Vt.) and <a href="https://cd.politicopro.com/member/140963" target="_blank" data-person-id="140963" class="">Elizabeth Warren</a> (D-Mass.) also have weighed in. Those critics accuse the drug companies of prioritizing profits over saving lives.</p><p class=" story-text__paragraph">“We
need to make the vaccines available everywhere if we're going to crush
this virus, and we need to make the public policy choices both in the
U.S. and at the WTO that puts patients first,” said Rep. Rosa DeLauro
(D-Conn.), one of the signatories on the House letter and chair of the
powerful House Appropriations Committee.</p><p class=" story-text__paragraph">The WTO has been deadlocked on the issue for six months, and so far the appeal from lawmakers and<a href="https://www.citizenstrade.org/ctc/wp-content/uploads/2021/02/COVIDTRIPSWaiverSignOnLetter_022621.pdf" target="_blank" class=""> over 400 health, labor, religious and other groups</a>
has not persuaded Biden to change the U.S. position against the waiver.
Since the WTO operates by consensus, all 164 members would have to
agree to support the measure for it to take effect. But backers of the
waiver request believe a U.S. switch in their direction would have a
transformative effect on other opponents.</p><p class=" story-text__paragraph">For
now, Biden administration officials only say they will make a decision
based on their analysis of how effective the waiver would be. They also
point to Biden’s pledge to provide $4 billion in contributions to COVAX,
the international alliance to distribute vaccines to 92 low- and
middle-income countries.</p><p class=" story-text__paragraph">“The
top priority of the United States is saving lives and ending the
pandemic, including by investing in COVAX and surging vaccine production
and delivery,” said Adam Hodge, a spokesperson for the Office of the
U.S. Trade Representative. “We are exploring every avenue to coordinate
with our global partners and are evaluating the efficacy of this
specific proposal by its true potential to save lives.”</p><p class=" story-text__paragraph" data-content-child-index="0-0">The
Trump administration’s opposition to the waiver was a rare instance of
solidarity with the European Union, which along with Japan, Canada, the
United Kingdom, Australia and several other WTO members also opposes
waiving the intellectual property protections.</p><p class=" story-text__paragraph" data-content-child-index="0-1">However,
it is typical of rich countries, which host major pharmaceutical
companies, to oppose any challenges to intellectual property rights from
poorer nations.</p><p class=" story-text__paragraph" data-content-child-index="0-2">The
bloc of mostly developed countries argue strong patent protections have
been key to the rapid development of the vaccines, and issuing a broad
waiver would undermine the ability of the industry to respond to a
future pandemic.</p><p class=" story-text__paragraph" data-content-child-index="0-3">Top
executives at 31 pharmaceutical companies, in a letter to Biden earlier
this month, said waiver proponents have offered no evidence that patent
and other protections are what is currently hindering vaccine
availability, rather than the expected lag between developing the
products and ramping up production to meet global demand.</p><p class=" story-text__paragraph" data-content-child-index="0-4">"Despite
the immense challenge of scaling manufacturing on novel technologies,
current estimates are that Covid-19 vaccine manufacturers will supply
approximately 10 billion doses by the end of 2021, enough to vaccinate
the entire current global vaccine eligible population," they added.</p><p class=" story-text__paragraph" data-content-child-index="0-5">At
least two companies — AstraZeneca and Novavax — have allowed
manufacturers in India, Japan and South Korea to produce their vaccines
under voluntary licensing agreements.</p><p class=" story-text__paragraph" data-content-child-index="0-6">But
the World Health Organization, which supports India and South Africa’s
waiver request, argues the terms of the voluntary license schemes being
offered by some patent holders are not sufficient to address the current
pandemic.</p><p class=" story-text__paragraph" data-content-child-index="0-7">The
Vatican, which has observer status at the WTO, has also jumped into the
debate. Quoting Pope Francis, the Holy See’s representative argued
during a meeting last month of the WTO’s intellectual property council
that the world should not allow the law of the marketplace and patents
to take precedence over the health of humanity.</p><p class=" story-text__paragraph" data-content-child-index="0-8">Supporters
of the waiver hope those and other moral arguments will resonate with
Biden, who is the U.S.’s second Roman Catholic president and was
photographed on his first day in office <a href="https://twitter.com/MikeOLoughlin/status/1352021904169820166/photo/1" target="_blank" class="">sitting in front of a picture of himself and the pontiff.</a></p><p class=" story-text__paragraph">They
also make an economic argument, saying any loss of pharmaceutical
company profits would be more than offset by global economic gains that
come from a quicker recovery, as well as the number of lives saved.</p><p class=" story-text__paragraph">The
next meeting to examine the issue at the WTO will take place over two
days in mid-April. That gives Katherine Tai, Biden’s newly confirmed
U.S. trade representative, some time to dig into the issue. If there's
no resolution, Biden could confront the issue head on later this year,
when G-20 leaders hold their annual meeting in October in Rome. Both
South Africa and India are members of the leading economy group, along
the United States, China, Germany, France and the EU as a whole. India
also could raise the issue when it attends the G7 summit in June as an
invited guest.</p><div class="container__column--story container__column center-horizontally">
<div class="story-text"><p class=" story-text__paragraph">Among major developing countries, only
Brazil is openly opposed, while China has said the waiver request
represents a good starting point for talks on any emergency trade
measures that should be taken. India, a major generic drug manufacturer,
claims the support of more than 100 countries for the proposal.</p><p class=" story-text__paragraph">The WTO’s new director general, Ngozi
Okonjo-Iweala, former co-chair of the alliance behind COVAX, has
suggested a “third way” solution to encourage vaccine patent holders to
enter into voluntary licensing agreements with drug manufacturers around
the world in order to scale up production.</p><p class=" story-text__paragraph">A group of <a href="https://www.cotton.senate.gov/imo/media/doc/Biden%20WTO%20IP%20letter.pdf" target="_blank" class="">four Republican senators</a> led by Tom Cotton of Arkansas also have urged Biden not to support the waiver.</p><p class=" story-text__paragraph">"Waiving all rights to intellectual
property would end the innovation pipeline and stop the development of
new vaccines or boosters to address variants in the virus. It also
wouldn’t increase the supply of vaccines because of the tremendous time
and resources needed to build new manufacturing plants and acquire the
know-how to produce these complex medicines," the senators wrote.</p><p class=" story-text__paragraph">But proponents of the waiver say the
drug manufacturers cannot be trusted when they say 10 billion doses will
be available by the end of year. Other estimates indicate it could be
as late as 2023 or 2024 until there are enough vaccines to treat the
world’s population, Rep. Jan Schakowsky (D-Ill.) said.</p><p class=" story-text__paragraph">“Time is also of the essence right now
because there are the variants that are developing,” Schakowsky said.
“The administration has made some moves in the right direction. But the
real answer is to allow for the manufacture of these vaccines.”</p></div></div><p class=" story-text__paragraph"><br class=""></p></div></div><div class=""><div class="">
Arthur Stamoulis<br class="">Citizens Trade Campaign<br class="">(202) 494-8826<br class=""><br class=""><br class=""><br class="">
</div>
<br class=""></div></body></html>